Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms in the 5,10-methylenetetrahydrofolate reductase (MTHFR), vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), monocyte chemoattractant protein-1 (MCP-1) and apolipoprotein E (ApoE) genes appear to be a genetic risk factor for atherosclerosis.
|
19148342 |
2009 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Upregulation of VEGF and NGFr, particularly in subjects with risk factors for atherosclerosis, reinforces the role of ischemia in BPH-induced modifications of the bladder.
|
28506859 |
2017 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, various human studies have revealed a high coincidence of VEGF and NOTCH polymorphisms with cardiovascular outflow tract anomalies, such as bicuspid aortic valves and Tetralogy of Fallot, next to predisposition for cardiovascular pathologies, including atherosclerosis and aortic valve calcification.
|
22683047 |
2012 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our goal was to study whether three variants of the VEGF gene, previously associated with VEGF production, are linked to atherosclerosis defined as carotid intima-media thickness (IMT) and as the risk of acute myocardial infarction (AMI).
|
19089753 |
2009 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The association between genetic variations of vascular endothelial growth factor (VEGF) gene and the risk for atherosclerosis has been hypothesized.
|
27704620 |
2017 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study identifies polymorphisms in the HIF1A and VEGF genes as potential genetic markers that indicate the predisposition to either AAA coexisting with peripheral atherosclerosis or AAA without such lesions, suggesting the genetic heterogeneity of this disease.
|
24657063 |
2015 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To determine the potential genotype differences in the vascular endothelial growth factor (VEGF) gene in diabetic patients, which might explain the difference in terms of the development of clinical vascular complications: great vessels atherosclerosis vs. retinopathy.
|
22064697 |
2012 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) plays a role in atherosclerosis-related diseases such as cerebrovascular or cardiovascular diseases.
|
21737794 |
2011 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
VEGF-A as an endogenous EL inhibitor could be therapeutically relevant in atherosclerosis by increasing systemic HDL cholesterol levels.
|
23102786 |
2012 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pearson correlation analysis showed a negative correlation of miR-126 with IMT and plaque area, but a positive association between VEGF and IMT and plaque area. miR-126 and VEGF are expected to become a valuable biomarker for monitoring the progression of atherosclerosis in uremic patients undergoing MHD.
|
30041762 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
It was unknown how hyperlipidemia, a risk factor that is closely associated with atherosclerosis of brain vessels in humans, influences vascular endothelial growth factor-induced angiogenesis and stroke recovery.
|
23559636 |
2013 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF), a key regulator of blood vessel function during angiogenesis, has been related to various diseases including atherosclerosis, neurodegenerative disorders and cancers.
|
17227476 |
2007 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
CTD_human |
VEGF polymorphisms and severity of atherosclerosis.
|
15937083 |
2005 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis.
|
9815864 |
1998 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Induction of vascular endothelial growth factor in balloon-injured baboon arteries. A novel role for reactive oxygen species in atherosclerosis.
|
9201024 |
1997 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells.
|
26959822 |
2016 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
Vascular endothelial growth factor (VEGF) has been noted in the pathogenesis of atherosclerosis.
|
17141247 |
2007 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study shows no proatherogenic effects of adenovirus-mediated gene transfers of VEGF-A, -B, -C, or -D in the LDLR/apoB48-deficient hypercholesterolemic mice, in which lipoprotein profile and atherosclerosis closely resemble those in human disease.
|
16129816 |
2005 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis.
|
11156961 |
2001 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Placental growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family cytokines and is associated with inflammatory progress of atherosclerosis.
|
20500895 |
2010 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, our report shows that the VEGF -2 578 polymorphism has an influence on CAD severity, possibly because of a reduced VEGF expression, suggesting a protective effect of VEGF in atherosclerosis.
|
19037583 |
2008 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased level of VEGF and decreased level of C-reactive protein, a biological marker that is closely related to atherosclerosis, were also observed from animals treated with the bilayered NPs, implicating ameliorated atherosclerosis.
|
28748694 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
VEGF and TGF-β1 may be involved in the development of type 2 diabetes (T2MD) atherosclerosis (AS).
|
30233664 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD40, G-CSF, IFN-γ, interleukin (IL)-1β, IL-6, MCP-1, MIP-3α, tumor necrosis factor-α (TNF-α), and VEGF were attenuated by TSA in atherosclerosis cytokine antibody arrays.
|
28646427 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
New CV events in subjects with T2D with manifest CVD were associated with higher baseline levels of inflammatory biomarkers (interleukin 6, chemokine ligand 3, pentraxin 3, and hs-CRP) and endothelial mitogens (hepatocyte growth factor and vascular endothelial growth factor A), whereas CV events in subjects with T2D without manifest CVD were associated with more severe baseline atherosclerosis (median carotid plaque area 30.4 mm<sup>2</sup> [16.1-92.2] vs. 19.5 mm<sup>2</sup> [9.5-40.5], <i>P</i> = 0.01).
|
30061319 |
2018 |